Discrimination between gnrh-i and gnrh-ii
CA 2421580 C · Owner: Oonk, Hendrica Berendina · Inventors: Turkstra, Jouwert Anne; Meloen, Robert Hans; Oonk, Hendrica Berendina
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A peptide that comprises a modified GnRH decapeptide sequence which allows for a testosterone level that is essentially non-detectable after vaccination with the peptide in a suitable dosage and/or allows for a immunogenic response that allows for the effective discrimination between GnRH-I and GnRH-II and a method for the immunocastration of pigs and for the treatment of prostate cancers of humans
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 11, 2001 and granted November 20, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 11, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 11, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.